{"id":"NCT00306592","sponsor":"Biogen","briefTitle":"Natalizumab Re-Initiation of Dosing","officialTitle":"An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2007-12","completion":"2008-02","firstPosted":"2006-03-24","resultsPosted":"2010-01-26","lastUpdate":"2017-03-21"},"enrollment":404,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"BIOLOGICAL","name":"BG00002 (natalizumab)","otherNames":["Tysabri"]}],"arms":[{"label":"Natalizumab","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to further evaluate the safety of natalizumab (Tysabri®) monotherapy by evaluating the risk of hypersensitivity and immunogenicity following re-exposure to natalizumab, and to confirm the safety of switching to natalizumab from interferon beta (IFN-β), glatiramer acetate (GA), or other multiple sclerosis (MS) therapies.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious AEs (SAEs)","timeFrame":"Baseline through Week 48","effectByArm":[{"arm":"300 mg Natalizumab IV Monthly","deltaMin":826,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":63,"countries":["United States","Canada"]},"refs":{"pmids":["24898925"],"seeAlso":["http://www.nationalmssociety.org","http://www.msactivesource.com"]},"adverseEventsSummary":{"seriousAny":{"events":61,"n":1094},"commonTop":["Multiple sclerosis relapse","Nasopharyngitis","Upper respiratory tract infection","Headache","Urinary tract infection"]}}